
LifeMD (LFMD) Stock Forecast & Price Target
LifeMD (LFMD) Analyst Ratings
Bulls say
LifeMD Inc. demonstrated a robust growth trajectory in its Telehealth segment, achieving a 14% year-over-year increase in active subscribers, culminating in a total of 310,818 by the end of 3Q25. Total revenue reached $60.2 million, reflecting a 12.7% year-over-year growth, with Telehealth revenue specifically growing by 17.4% to $47.3 million, indicating a strong demand for virtual healthcare services. Additionally, the company's gross margin expanded to 87%, showcasing an improved revenue mix that contributes to its positive financial outlook.
Bears say
LifeMD Inc. faces several fundamental challenges that contribute to a negative outlook, including lower-than-projected growth in telehealth revenue, difficulties in acquiring and retaining new patients, and an inability to achieve profitability. The company reported revenue of $60.2 million, which was a 13% year-over-year growth but fell short of consensus expectations, while adjusted EBITDA of $5.1 million represented a 20% increase yet also missed projections. Additionally, the reduction in full-year 2025 revenue guidance, now anticipated to be between $192 million and $193 million, alongside increased competition and potential dilution risks, heightens concerns regarding LifeMD's financial performance and stability.
This aggregate rating is based on analysts' research of LifeMD and is not a guaranteed prediction by Public.com or investment advice.
LifeMD (LFMD) Analyst Forecast & Price Prediction
Start investing in LifeMD (LFMD)
Order type
Buy in
Order amount
Est. shares
0 shares